3 Results for "

PC3-PIP prostate cancer cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "PC3-PIP prostate cancer cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-160528
IBG3 is a bivalent molecular glue degrader that targets BRD2 and BRD4, with an EC50 of 32 nM and a Kd of 0.6 µM against human BRD4. IBG3 exhibits selectivity for BRD2 and BRD4 over BRD3. By recruiting the DCAF16 E3 ligase, IBG3 cis-binds to the tandem bromodomains of BRD2 and BRD4, enhances BRD-DCAF16 binding affinity, promotes ubiquitination and proteasomal degradation, and does not degrade isolated bromodomains. IBG3 lacks degradation selectivity for PSMA-positive and PSMA-negative prostate cancer cells, but shows lower in vivo antitumor efficacy than the PSMA-targeting conjugate IBG-P3, and can be used in prostate cancer-related research .
loading...
    loading...
Cat. No.: HY-181830
Target:  

PD-1/PD-L1 PSMA LYTACs

Research Areas:  

Cancer

Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-182240
Target:  

PSMA

Research Areas:  

Cancer

Cy5-ZW2-617 is a PSMA ligand with a IC50 of 4.39 nM. Cy5-ZW2-617 specifically binds to PSMA and is thereby internalized by PSMA-positive cells. Cy5-ZW2-617 shows uptake in PSMA-positive tumor cells and tumor xenografts in mice. Cy5-ZW2-617 can be used for the research of prostate cancer .
loading...
    loading...